A model-to-mechanism burden of proof is proposed that distinguishes prediction from explanation, imputation from observation, attribution from causality, cross-layer coherence from mechanism, and diagnostic performance from biological validity to strengthen, not constrain, computational microbiome science.
Abstract
Artificial intelligence and machine-learning-assisted multi-omics have expanded the scale and ambition of microbiome research, but they have also sharpened an older interpretive problem. Biologically plausible structure is too easily mistaken for biological explanation. This Perspective defines the multi-omics fallacy as claim inflation that occurs when integrating microbial, host, environmental, spatial, and clinical data is assumed to move interpretation from association toward verified mechanism without a corresponding gain in measurement, localization, temporal resolution, functional linkage, or perturbation. The risk is not that computational integration lacks value. It is that predictions, imputations, inferred pathways, feature attributions, and cross-layer networks can acquire mechanistic authority before their biological status has been established. In microbiome science, where stool readouts, taxonomic abundance, inferred function, and predicted metabolites often serve as proxies for host-microbial interaction, this slippage can make uncertain claims appear more complete than the evidence allows. Computational confidence can amplify structured artifact when systematic error becomes learnable. This Perspective proposes a model-to-mechanism burden of proof that distinguishes prediction from explanation, imputation from observation, attribution from causality, cross-layer coherence from mechanism, and diagnostic performance from biological validity. This framework is intended to strengthen, not constrain, computational microbiome science by clarifying which outputs support classification or hypothesis generation and which require direct measurement, localization, temporal analysis, functional validation, or perturbation. Used this way, computational models can help expose uncertainty, prioritize experiments, identify fragile claims, and sharpen biological questions. The result would be a more powerful form of computational microbiome science, one in which models do not stand in for mechanisms but guide the work needed to earn them.
Joint Robust Principal Component Analysis (Joint-RPCA), a method designed with these statistical properties in mind and broadly applicable to multi-omics settings with similar challenges, reveals replicable and interpretable multi-omic patterns.
Bianca Cordazzo Vargas, C. Martino, A. Dilmore et al.· Molecular Systems Biology· 1 citation
The human gut is now understood less as a passive tube and more as a densely populated, metabolically active organ in its own right — one whose genetic repertoire dwarfs that of its host. When this ecosystem drifts into dysbiosis, the consequences ripple outward into inflammatory, metabolic, and even neuropsychiatric disease. What has changed in the last decade, though, is not simply our awareness of this relationship but our capacity to measure it, model it, and — increasingly — to intervene in it with rational, patient-specific precision. We conducted a structured narrative synthesis of the peer-reviewed literature (2017–2026) addressing metagenomic and multi-omics profiling, computational and machine-learning platforms, and clinical bioactive design in the gut microbiome. Across the synthesized evidence, dysbiosis emerged as a structured — not stochastic — ecological state, reproducibly separable from eubiotic communities using ordination and machine-learning classifiers, with diagnostic performance reaching an area under the curve of 0.98 when metagenomic and metabolomic layers were fused. Genome-scale metabolic reconstructions predicted individualized short-chain fatty acid deficits and successfully guided personalized prebiotic supplementation in the majority of simulated Crohn's disease patients. Engineered live biotherapeutics and nanoparticle-based delivery platforms demonstrated proof-of-concept safety and target-specific payload release in early clinical and preclinical work, though translational reach remains constrained by sample-collection heterogeneity and a pronounced geographic skew in reference databases. Personalized microbiome medicine is arguably no longer a speculative frontier; the computational scaffolding and biological rationale are largely in place. What now stands between bench and bedside is less a scientific gap than an infrastructural one — standardization, validation, and equitable data representation.
The human microbiome functions as a metabolically active organ whose biochemical output is continuously integrated with host physiology. Conventional microbiome surveys, built largely on taxonomic profiling, capture community composition and diversity but resolve neither the functional capacity of these communities nor the bidirectional metabolic exchange that links them to the host. A central limitation is that taxonomy is a poor proxy for function: phylogenetically distinct organisms can perform equivalent reactions, and closely related taxa can diverge metabolically. Resolving host microbiome interactions, therefore, requires integration across heterogeneous, high-dimensional molecular layers, such as metagenomics, metatranscriptomics, proteomics, metabolomics, and host genomic and phenotypic data at a scale and complexity that exceeds classical analytical pipelines. Artificial intelligence (AI) has emerged as a complementary framework for this problem. Machine learning, deep learning, and graph-based models can integrate multi-omics data, infer latent metabolic structure, predict microbial functional potential, and model microbe-metabolite-host relationships as connected networks rather than isolated parts. These approaches have sharpened the discovery of disease-associated microbial and metabolic signatures and candidate therapeutic targets, and they underpin emerging precision medicine applications, including individualized risk stratification, biomarker discovery, and treatment response prediction. Substantial barriers remain, however, including incomplete and non-standardized reference data, limited model interpretability, vulnerability to bias and overfitting, and a shortage of prospective clinical validation. Continued progress in foundation models, real-time microbiome monitoring, and patient-specific metabolic modelling is expected to move the field from descriptive association toward predictive, preventive, and personalized clinical application.
To Lawal, James Momoh, M. Odedele et al.· Australian Journal of Biomed...· 0 citations
The microbiota is increasingly recognized as an active component of host biology, influencing various host phenotypes. Advances in high-throughput sequencing and the emergence of the holobiont perspective have raised expectations regarding hologenomic-informed prediction. Yet, whether and under which conditions integrating microbiota and genomic data meaningfully improves phenotypic prediction remains unclear. The biological characteristics of the microbiota, including but not limited to transmission mechanisms, environmental effects and interactions with host genetics, complicate their integration into classical evaluation frameworks. In addition, microbiota datasets are high-dimensional, highly dispersed, sparse and compositional. Finally, analytical choices such as the taxonomic granularity considered for aggregation or the similarity matrix used in prediction models may impact downstream inference and prediction accuracy. Here we explore these challenges using a comprehensive set of transgenerational hologenomic simulations. By generating controlled and contrasted biological scenarios across a broad parameter space, we examine how microbiota granularity, variance structure and host modulation influence (i) the estimation of variance components and (ii) the accuracy of phenotypic prediction. We show that the added value of hologenomic, compared to genomic prediction, is highly context dependent. Our results provide a structured framework to interrogate when and how integrating microbiota may enhance phenotypic prediction in breeding applications.
Solène Pety, Ingrid David, Andrea Rau et al.· 0 citations
Whether combining microbiome data from multiple body sites improves prediction, and whether different sites carry complementary or redundant information, are distinct questions that most studies conflate into a single accuracy metric. This work makes two contributions, one methodological and one biological, using paired stool and oral cavity microbiome samples from 44 subjects across two age groups, healthy adults and newborns (Ferretti et al., 2018). Methodologically, we show that a subject-matched fusion design combined with SHAP-based (SHapley Additive exPlanations) site attribution can detect complementary information between body sites even when no measurable accuracy gain results. This is a pattern that conventional model comparison would misread as a null result. Gut (stool) composition alone achieved near-perfect classification (area under the receiver operating characteristic curve, AUC = 1.00), and combined stool-oral models never exceeded this ceiling. A null baseline, bootstrap confidence intervals, and preprocessing sensitivity checks confirmed that this ceiling reflects genuine biological signal rather than an artifact. Despite the flat accuracy curve, SHAP analysis of the fused model showed that oral cavity features carried more total feature importance than stool features (58.1% versus 41.9%), indicating that the model draws on real, non-redundant information from both sites. Biologically, the taxa driving this pattern include Malassezia restricta, Staphylococcus epidermidis, and Prevotella melaninogenica. These taxa behave in a manner consistent with their established roles as early colonizers of the neonatal gut, skin, and oral cavity, once their model-specific behavior is verified directly against abundance data rather than inferred from the literature alone. An independent, substantially larger paired-cohort study using a different analytical method reports a compatible pattern. Together, these results support a model of oral-gut microbiome maturation as two distinct, complementary processes, and demonstrate that detecting this kind of relationship requires examining a model’s internal reasoning rather than its accuracy alone.
Chowdhury Aseer Ruthbah, Talim Hossain Sadi, Nur E. Shiratun Jahan et al.· bioRxiv· 0 citations
Microbiome research has moved from cataloging community composition to asking what these communities do, but “function” is often used to describe fundamentally different levels of evidence. Functional claims may refer to functional capacity (what is encoded), functional realization (what molecular functions are actively engaged under specific conditions), or functional impact (the resulting consequences for hosts, microbial communities, or ecosystems). In this Perspective, we examine how functional annotations in microbiome research generate biological meaning and why current approaches support different kinds of inference. We propose a framework that distinguishes three levels of functional inference: capacity, realization, and impact. Homology-based, domain-centric, pathway-based, machine learning-driven, and multi-omics approaches each contribute differently to these levels, but none alone captures microbiome function in full. We argue that microbiome function should be interpreted as a hierarchy of inferences rather than a single property. Recognizing this distinction should improve how functional findings are interpreted, reported, and compared across microbiome studies. Accordingly, functional studies should explicitly state whether their conclusions concern capacity, realization, or impact, thereby clarifying the evidential basis of functional claims and improving their interpretation and comparison across microbiome studies.
Rajesh Kumar Bajiya, Rania Agabi, J. García et al.· Environmental Microbiome· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
